Welcome to our dedicated page for Johnson & Johnson SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Johnson & Johnson (NYSE: JNJ) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large New Jersey–incorporated healthcare issuer with common stock and multiple series of notes listed on the New York Stock Exchange, Johnson & Johnson reports material events, financial results and capital structure details through forms such as 10-K, 10-Q and 8-K.
Recent Form 8-K filings illustrate how Johnson & Johnson uses current reports to communicate key developments. For example, the company has filed 8-Ks to announce quarterly sales and earnings results for specific fiscal quarters, and to disclose its intent to separate its Orthopaedics business. These filings also list the securities registered under Section 12(b) of the Exchange Act, including the JNJ common stock and various notes with maturities extending from the late 2020s through the 2050s, each with its own NYSE trading symbol.
On this page, users can review Johnson & Johnson’s periodic reports for detailed information on its Innovative Medicine and MedTech operations, risk factors, research and development spending, and manufacturing and investment plans. Annual reports on Form 10-K and quarterly reports on Form 10-Q provide management’s discussion and analysis, segment information and notes to the financial statements, while current reports on Form 8-K highlight specific corporate actions, clinical or regulatory milestones and financing activities as they occur.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand topics such as revenue drivers, major therapeutic areas, MedTech initiatives, capital allocation decisions and announced business changes like the planned Orthopaedics separation. The platform also surfaces relevant items related to Johnson & Johnson’s registered debt securities and any disclosed board or governance actions. For investors, analysts and researchers, this page offers a structured view of Johnson & Johnson’s regulatory record, with real-time updates as new filings are posted to EDGAR.
Johnson & Johnson: Schedule 13G/A Amendment No. 10 — The Vanguard Group reports 0 shares (0%) beneficially owned.
The filing states that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries report holdings separately in reliance on SEC Release No. 34-39538. The Vanguard Group certifies it no longer has beneficial ownership of the securities held by those subsidiaries and reports 0 shares beneficially owned as of the amendment signature date 03/26/2026.
Johnson & Johnson filed an amended Form 13F-HR restating and adding holdings information for its institutional investment manager report.
The amendment is Amendment No. 1, signed by Marc Larkins, Secretary on 03-18-2026. The Form 13F Information Table shows 17 entries with a total reported market value of $555,047,952. One other included manager is listed: Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson submitted an amended Form 13F-HR restating and updating its institutional holdings report. The amendment lists 20 holdings entries with a total reported value of $503,922,707 and identifies 1 other included manager, Johnson & Johnson Innovation - JJDC, Inc.
The report is signed by Marc Larkins, Secretary, and the filing indicates it adds new holdings entries as part of the amendment.
HEWSON MARILLYN A reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Marillyn A. Hewson reported routine compensation-related awards of Deferred Share Units (DSUs), not open-market stock trades. On March 10, 2026, she received 206.4920 DSUs valued at $242.1400 each, bringing her holdings to 14512.9400 DSUs.
The filing also reflects a prior DSU award of 75.2560 units on March 4, 2025 at $166.1000 per unit. These DSUs represent deferred cash retainers under the company’s Deferred Fee Plan for Directors, are settled in cash when her board service ends, and track the fair market value of one share of common stock plus dividend equivalents.
Pinto Daniel E reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Daniel E. Pinto received a grant of 129.058 Deferred Share Units, credited at a reference price of $242.14 per unit, in connection with deferring his cash director retainer. These units track the value of one common share each and are to be settled in cash when his board service ends, bringing his total deferred units to 462.069 including dividend-equivalent accruals.
Johnson & Johnson director Eugene A. Woods received a grant of deferred share units as part of his board compensation. On this date, he acquired 154.869 Deferred Share Units (DSUs), each valued at 242.1400 per unit, bringing his total DSU balance to 5,240.094 units.
The DSUs represent deferred cash retainer fees under the company’s Amended and Restated Deferred Fee Plan for Directors and are to be settled in cash when his directorship ends. Each DSU tracks the fair market value of one share of Johnson & Johnson common stock, and the balance includes dividend equivalent rights credited on outstanding DSUs.
Johnson & Johnson is asking shareholders at its April 23, 2026 virtual annual meeting to elect 12 directors, approve executive pay on an advisory basis, ratify PricewaterhouseCoopers as 2026 auditor, and vote on a shareholder proposal for an independent board chair, which the Board recommends against.
The Board remains mostly independent, with a combined Chairman/CEO structure balanced by a powerful Lead Independent Director role and fully independent key committees. The proxy details board refreshment, committee responsibilities, Enterprise Risk Management, cybersecurity and sustainability oversight, and a pay-for-performance program heavily weighted to long-term equity incentives.
Directors and executives show meaningful stock ownership and strong Say on Pay support in 2025, while large institutional holders such as Vanguard, BlackRock and State Street are disclosed. The Board highlights active shareholder engagement and oversight of a potential separation of the Orthopaedics business through a Special Committee.
Johnson & Johnson executive Robert J. Decker, VP Corporate Controller, exercised employee stock options for 4,075 shares of common stock on February 27, 2026 and immediately received those shares at an exercise price of $115.67 per share. He then sold 4,075 shares of common stock the same day in an open-market transaction at an average price of $247.87 per share, leaving him with 23,682 shares of common stock held directly.
In addition to his direct holdings, Decker is reported as having 134 shares of common stock held indirectly through an ESOP under the Johnson & Johnson Savings Plan and 646 shares held indirectly through a 401(k) plan, both as of the plans’ most recent reporting date of February 28, 2026.